Howard Hughes Medical Institute Investigator; Gret
leader and innovator
United States of America
Phillip Zamore is a leader and innovator in the understanding of RNAi and development of related therapeutic approaches, including expressed RNAi. His lab focuses on studying RNA silencing pathways in eukaryotes, including the RNAi, microRNA and PIWI-interacting RNA pathways, and has helped explain how these pathways produce small silencing RNAs and how those small RNAs repress the expression of genes, transposons and viruses. Dr. Zamore is a Howard Hughes Medical Institute investigator, Gretchen Stone Cook Chair of Biomedical Sciences, professor of biochemistry and molecular pharmacology, and chair of the RNA Therapeutics Institute at the University of Massachusetts Medical School. Dr. Zamore was a 2000 Pew Scholar in Biomedical Sciences and a 2002 W. M. Keck Distinguished Young Scholar in Medical Research. He is the author of numerous high-impact papers in molecular biology and genetics and was the 2009 recipient of the ASBMB Schering-Plough Award. Dr. Zamore is a co-founder of Alnylam Pharmaceuticals and currently sits on the company’s scientific advisory board. Dr. Zamore holds an A.B. and Ph.D. from Harvard University, both in biochemistry and molecular biology.
RNAi and development of related therapeutic approaches, including expressed RNAi